Regeneron(REGN) ACCESSWIRE Newsroom·2025-01-16 23:15Group 1 - Investors who lost money on Regeneron Pharmaceuticals, Inc. (REGN) are encouraged to contact Levi & Korsinsky regarding a pending class action lawsuit [1] - The class action is aimed at addressing potential losses incurred by investors due to undisclosed information or misleading statements related to Regeneron's performance [1] - The announcement highlights the importance of investor awareness and the legal recourse available for those affected by the company's actions [1] Group 2 - The article emphasizes the ongoing legal challenges faced by Regeneron Pharmaceuticals, which may impact investor confidence and stock performance [1] - It suggests that the outcome of the class action could have significant implications for the company's reputation and financial standing [1] - The situation underscores the broader context of investor protection and corporate accountability within the pharmaceutical industry [1]